Michael Koldehoff

Summary

Affiliation: University of Duisburg-Essen
Country: Germany

Publications

  1. ncbi WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells
    Ahmet H Elmaagacli
    Department of Bone Marrow Transplantation, University Hospital of Essen, Hufelandstr 55, 45122 Essen, Germany
    Haematologica 90:326-34. 2005
  2. ncbi Growth factor-independent 1B gene (GFI1B) is overexpressed in erythropoietic and megakaryocytic malignancies and increases their proliferation rate
    Ahmet H Elmaagacli
    Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
    Br J Haematol 136:212-9. 2007
  3. ncbi Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma
    Michael Koldehoff
    Department of Bone Marrow Transplantation, University Hospital of Duisburg Essen, Hufelandstr 55, 45122 Essen, Germany
    J Leukoc Biol 84:561-76. 2008
  4. ncbi Modulating impact of human chorionic gonadotropin hormone on the maturation and function of hematopoietic cells
    Michael Koldehoff
    Department of Bone Marrow Transplantation, West German Cancer Center, Medical School of University of Duisburg Essen, University Hospital of Duisburg Essen, Essen, Germany
    J Leukoc Biol 90:1017-26. 2011
  5. ncbi Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia
    M Koldehoff
    Department of Bone Marrow Transplantation, University of Duisburg Essen, Hufelandstr 55, 45122 Essen, Germany
    Clin Exp Med 7:47-55. 2007
  6. ncbi Gene profiling of growth factor independence 1B gene (Gfi-1B) in leukemic cells
    Michael Koldehoff
    Department of Bone Marrow Transplantation, University Hospital of Duisburg Essen, Essen, Germany
    Int J Hematol 87:39-47. 2008
  7. ncbi Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib
    Michael Koldehoff
    Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital of Duisburg Essen, Hufelandstr 55 45122 Essen, Germany
    Haematologica 95:388-97. 2010
  8. ncbi Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation
    Nina K Steckel
    Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
    Transplantation 83:1518-20. 2007
  9. ncbi T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors
    Markus Ditschkowski
    Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
    Haematologica 92:558-61. 2007
  10. ncbi Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor
    Ahmet H Elmaagacli
    Department of Bone Marrow Transplantation, University Hospital of Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Transplantation 79:1741-7. 2005

Detail Information

Publications26

  1. ncbi WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells
    Ahmet H Elmaagacli
    Department of Bone Marrow Transplantation, University Hospital of Essen, Hufelandstr 55, 45122 Essen, Germany
    Haematologica 90:326-34. 2005
    ..Furthermore, we wanted to evaluate whether the additional use of BCR-ABL siRNA could increase the anti-leukemic effects of WT1 siRNA in chronic myeloid leukemia (CML) cells...
  2. ncbi Growth factor-independent 1B gene (GFI1B) is overexpressed in erythropoietic and megakaryocytic malignancies and increases their proliferation rate
    Ahmet H Elmaagacli
    Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
    Br J Haematol 136:212-9. 2007
    ..Our data indicate that GFI1B plays a major role in AML-M6 and AML-M7 and qualifies as a target for anti-leukaemic strategies in these malignancies...
  3. ncbi Small-molecule inhibition of proteasome and silencing by vascular endothelial cell growth factor-specific siRNA induce additive antitumor activity in multiple myeloma
    Michael Koldehoff
    Department of Bone Marrow Transplantation, University Hospital of Duisburg Essen, Hufelandstr 55, 45122 Essen, Germany
    J Leukoc Biol 84:561-76. 2008
    ....
  4. ncbi Modulating impact of human chorionic gonadotropin hormone on the maturation and function of hematopoietic cells
    Michael Koldehoff
    Department of Bone Marrow Transplantation, West German Cancer Center, Medical School of University of Duisburg Essen, University Hospital of Duisburg Essen, Essen, Germany
    J Leukoc Biol 90:1017-26. 2011
    ..Rejection of allogeneic skin grafts was delayed in female mice receiving hCG. We conclude that hCG may be useful for the induction of immune tolerance in solid organ transplantation...
  5. ncbi Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia
    M Koldehoff
    Department of Bone Marrow Transplantation, University of Duisburg Essen, Hufelandstr 55, 45122 Essen, Germany
    Clin Exp Med 7:47-55. 2007
    ..Our findings imply that the clinical application of synthetic siRNA is feasible, safe and has real potential for genetic-based therapies using synthetic non-viral carriers...
  6. ncbi Gene profiling of growth factor independence 1B gene (Gfi-1B) in leukemic cells
    Michael Koldehoff
    Department of Bone Marrow Transplantation, University Hospital of Duisburg Essen, Essen, Germany
    Int J Hematol 87:39-47. 2008
    ..Our data indicate that Gfi-1B signalling is important for commitment and maturation of hematopoietic cell populations...
  7. ncbi Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib
    Michael Koldehoff
    Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital of Duisburg Essen, Hufelandstr 55 45122 Essen, Germany
    Haematologica 95:388-97. 2010
    ..We, therefore, evaluated specific BCR-ABL small interfering RNA silencing in BCR-ABL-positive cell lines, including those resistant to imatinib and particularly those with the T315I mutation...
  8. ncbi Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation
    Nina K Steckel
    Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
    Transplantation 83:1518-20. 2007
    ..Our presented data shows the feasibility of the detection of JAK2 gene mutation by real-time PCR as a minimal residual disease marker after transplant...
  9. ncbi T-cell depletion prevents from bronchiolitis obliterans and bronchiolitis obliterans with organizing pneumonia after allogeneic hematopoietic stem cell transplantation with related donors
    Markus Ditschkowski
    Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
    Haematologica 92:558-61. 2007
    ..The data confirm a strong association between T-cell activity, chronic GVHD, BO and BOOP and point out the impact of T lymphocytes in the pathomechanism of BOOP...
  10. ncbi Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor
    Ahmet H Elmaagacli
    Department of Bone Marrow Transplantation, University Hospital of Essen, Hufelandstrasse 55, 45122 Essen, Germany
    Transplantation 79:1741-7. 2005
    ....
  11. ncbi Quantitative analysis of chimerism after allogeneic stem cell transplantation by real-time polymerase chain reaction with single nucleotide polymorphisms, standard tandem repeats, and Y-chromosome-specific sequences
    Michael Koldehoff
    Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
    Am J Hematol 81:735-46. 2006
    ..0, P < 0.0001). We conclude that the use of real-time SNP or Y-PCR may be superior to the STR-PCR or interphase XY-FISH methods in detecting patients who are at high risk for relapse after transplant...
  12. ncbi Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia
    Michael Koldehoff
    Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
    Methods Mol Biol 487:451-66. 2009
    ..Our findings imply that the clinical application of synthetic siRNA is feasible, safe and has real potential for genetic-based therapies using synthetic nonviral carriers...
  13. ncbi Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation
    Ahmet H Elmaagacli
    Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
    Transplantation 81:247-54. 2006
    ....
  14. ncbi Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients
    Ahmet H Elmaagacli
    Department of Bone Marrow Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg Essen, Essen, Germany
    Blood 118:1402-12. 2011
    ..0001). This is the first report that demonstrates an independent and substantial reduction of the leukemic relapse risk after early replicative HCMV infection in a homogeneous population of adult acute myeloid leukemia patients...
  15. ncbi Dynamic International Prognostic Scoring System scores, pre-transplant therapy and chronic graft-versus-host disease determine outcome after allogeneic hematopoietic stem cell transplantation for myelofibrosis
    Markus Ditschkowski
    Department of Bone Marrow Transplantation, WTZ, University Hospital of Essen, Essen, Germany
    Haematologica 97:1574-81. 2012
    ..The aim of this study was to assess disease-specific and transplant-related risk factors that influence post-transplant outcome in patients with myelofibrosis...
  16. ncbi Improved outcome of hematopoietic SCT in patients with homozygous gene variant of Toll-like receptor 9
    A H Elmaagacli
    Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
    Bone Marrow Transplant 44:295-302. 2009
    ..In vitro studies using CpG-rich ODNs showed an upregulation of TLR9 expression in cell lines with CC gene variant, but not in cell lines with wild-type gene...
  17. ncbi Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation
    A H Elmaagacli
    Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
    Bone Marrow Transplant 40:659-64. 2007
    ..These results suggest that genotyping for CYP450 2C19 can help to identify patients with higher risk for TRM...
  18. ncbi Successful treatment of EBV PTLD with CNS lymphomas with the monoclonal anti-CD20 antibody rituximab
    Lambros Kordelas
    Department of Bone Marrow Transplantation, University Hospital Essen, Germany
    Onkologie 31:691-3. 2008
    ..PTLD may involve several organs like liver, lungs, kidney, spleen, and small intestine. PTLD with central nervous system (CNS) involvement only has been reported in very few cases so far...
  19. ncbi Myeloablative allogeneic hematopoietic stem cell transplantation in elderly patients
    M Ditschkowski
    Department of Bone Marrow Transplantation, University Hospital of Essen, Hufelandstr, Essen, Germany
    Clin Transplant 20:127-31. 2006
    ..0001) were identified. These results show that hematopoietic SCT following myeloablative conditioning is also applicable to elderly patients whereas disease stage and high-grade GVHD represent the essential prognostic factors for outcome...
  20. ncbi Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia
    M Koldehoff
    Department of Bone Marrow Transplantation, University Hospital of Essen, Hufelandstr, 55, 45122 Essen, Germany
    Bone Marrow Transplant 34:1047-50. 2004
    ..All other patients were alive at the time of analysis. Our findings suggest that the outcome of allogeneic or syngeneic transplantation in patients with aCML may not be worse than the outcome of transplantation for BCR-ABL-positive CML...
  21. ncbi Modern management of respiratory failure due to pulmonary mycoses following allogeneic hematopoietic stem-cell transplantation
    Michael Koldehoff
    Department of Bone Marrow Transplantation, University Hospital Essen, 45122 Essen, Germany
    Am J Hematol 79:158-63. 2005
    ....
  22. ncbi Caspofungin as second-line therapy for fever of unknown origin or invasive fungal infection following allogeneic stem cell transplantation
    R Trenschel
    Department of Bone Marrow Transplantation, University Hospital Essen, Essen, Germany
    Bone Marrow Transplant 35:583-6. 2005
    ..CAS is a promising alternative in patients with IFI and fever of unknown origin in the setting of allogeneic SCT...
  23. ncbi Outcome of allogeneic stem cell transplantation in patients with myelofibrosis
    M Ditschkowski
    Department of Bone Marrow Transplantation, University Hospital of Essen, Hufelandstr 55, 45122 Essen, Germany
    Bone Marrow Transplant 34:807-13. 2004
    ..Our data suggest that transplantation should be taken into consideration before poor prognostic variables develop...
  24. ncbi Successful treatment of patients with respiratory failure due to fungal infection after allogeneic hematopoietic stem cell transplantation
    M Koldehoff
    Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
    Transpl Infect Dis 7:137-45. 2005
    ....
  25. ncbi Relation of an interleukin-23 receptor gene polymorphism to graft-versus-host disease after hematopoietic-cell transplantation
    A H Elmaagacli
    Department of Bone Marrow Transplantation, University Hospital of Essen, Essen, Germany
    Bone Marrow Transplant 41:821-6. 2008
    ..Among recipients of hematopoietic cells from HLA-identical donors, the IL-23R (Arg381Gln) gene variant on the donor side has a protective effect on the occurrence of acute GVHD in recipients after transplantation...
  26. ncbi No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis
    Markus Ditschkowski
    Biol Blood Marrow Transplant 12:1350-1. 2006